A new year, a new Journal

Abstract

Let us start this first editorial of 2018 with wishing you all a marvelous year where most of your dreams come true.In the last years, the editors of Rhinology felt often very unhappy when again we had to refuse papers send to us for Rhinology. Unfortunately, every year we can only accept around 15% of the papers we receive. With pain in our hearts, we often have to refuse papers of good quality but just not innovative enough or with slight methodological imperfections.The editorial board of Rhinology recognized this feeling and we decided to start a new journal: Rhinology Online to have space for all those papers that are good but just do not make the cut for Rhinology. Rhinology Online is a journal of the European Rhinologic Society, and will provide a platform for the dissemination of rhinologic research and reviews, as well as position papers, task force reports and guidelines, amongst an international scientific audience.Rhinology Online is a peer-reviewed, Open Access journal that will accept original research articles, review articles, protocols of clinical studies, letters to the editor, position papers, task force reports and guidelines and case reports in rhinology.Open access publishing enables free access to all content ensuring a wide dissemination of articles; the electronic format and expert peer review allows for very rapid publication. Publications will be available in Pubmed within a week after acceptance.Rhinology Online is an international journal reaching out far beyond the borders of Europe, and invites clinicians and researchers from all countries of the world to contribute.We look forward to have a modern lively journal with a lot of discussion. Please have look at the website: www.rhinologyonline.org and start sending in your papers.In this issue of Rhinology, a number of very interesting papers can be found. Two systematic reviews are presented. One on the effect of intranasal bevacizumab in the treatment of Hereditary haemorrhagic telangiectasia (HHT) -related epistaxis.Bevacizumab is a selective recombinant human antibody against VEGF -A isomers. It has also become first-line treatment for symptomatic hepatic AVMs in HHT, and based on this success, several studies have analysed the effect of bevacizumab on other HHT outcomes including epistaxis (1) . However, despite initial promising results, it remains unclear whether the agent provides any true benefit in epistaxis outcome (1) . Two years ago, the same authors published an excellent overview of all potential treatment options in HHT (2) in which they presented a treatment algorithm based on tamoxifen, followed by/ combined with ktp laser, septodermoplasty and finally nasal closure by the Lund modification of the Young's procedure (3) .The other review is very timely and summarizes the possibilities to treat CRSwNP with monoclonal antibodies. In the last years a number of studies has appeared that show effectiveness of anti-IgE (Omalizumab) (4-6) , anti-IL-5 (Mepolizumab) (7) and antiIL4Ra (Dupilumab) (8) .In CRSwNP our medical trea...